Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced it will present at Stifel’s 2020 Immunology and Inflammation Virtual Summit on October 1, 2020, at 9:00 a.m. ET. Cedric Francois, M.D., Ph.D., will participate in a panel discussing “The Evolution of Complement Targeted Therapies.” The event can be accessed live via webcast on the company’s website, with a replay available for 90 days post-event. Apellis specializes in developing therapies for diseases linked to complement cascade activation.

WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at Stifel’s 2020 Immunology and Inflammation Virtual Summit on Thursday, October 1, 2020 at 9:00 a.m. ET.

Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a panel discussion titled “The Evolution of Complement Targeted Therapies.” The event will be available live via webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. For more information, please visit http://apellis.com.

Investor Contact:
Sam Martin / Maghan Meyers
Argot Partners
sam@argotpartners.com / maghan@argotpartners.com
212.600.1902

FAQ

When is Apellis Pharmaceuticals presenting at the Stifel 2020 Summit?

Apellis Pharmaceuticals will present at Stifel’s 2020 Immunology and Inflammation Virtual Summit on October 1, 2020, at 9:00 a.m. ET.

Who will represent Apellis Pharmaceuticals at the summit?

Cedric Francois, M.D., Ph.D., the co-founder and CEO of Apellis, will participate in a panel discussion at the summit.

What is the topic of Apellis Pharmaceuticals' panel discussion?

The topic of the panel discussion is 'The Evolution of Complement Targeted Therapies.'

How can I watch the Apellis Pharmaceuticals presentation?

The presentation can be watched live via webcast on the company's website during the event.

Will there be a replay available for the Apellis Pharmaceuticals summit presentation?

Yes, a replay of the webcast will be available for 90 days following the event.

What is Apellis Pharmaceuticals known for?

Apellis Pharmaceuticals is known for developing targeted therapies for diseases associated with uncontrolled activation of the complement cascade.